Monday, July 18, 2016

BRIEF-Biogen SB5 accepted for review by European Medicines Agency

* Sb5, an adalimumab biosimilar referencing humira,

accepted for review by european medicines agency

Further company coverage:

(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223

8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)